Merck KGaA acquires US firm ProteoPlex
Germany's Merck KGaA says that, through its US subsidiary EMD Biosciences, it has acquired the USA-based, privately-owned R&D company ProteoPlex, which specializes in functional genomics and proteomics. The new acquisition will be fully integrated into EMD.
Both partners agreed not to disclose financial details of the transaction, but Merck noted that it will give the group the opportunity to gain access to the emerging microarray market, projected to approach a value of $2 billion by 2008. ProteoPlex was formed in 2001 with former management, R&D personnel and technology of Incyte.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze